Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2008

01.09.2008

Analysis of Clinical Applicability of the Breast Cancer Nomogram for Positive Sentinel Lymph Node: The Canadian Experience

verfasst von: Éric Poirier, MD, FRCSC, Lucas Sideris, MD, FRCSC, Pierre Dubé, MD, MSc, FRCSC, FACS, Pierre Drolet, MD, FRCPC, Sarkis H. Meterissian, MD, FRCSC, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

A Breast Cancer Nomogram (BCN) for predicting nonsentinel lymph node (NSLN) involvement has been developed and prospectively tested in several series. However, its clinical applicability has never been tested among surgeons.

Methods

The BCN was applied to 209 SLN-positive patients. Its performance was assessed by the area under the receiver–operating characteristic (ROC) curve. Surgeons in Quebec were surveyed to determine the predicted NSLN positivity below which they would not dissect the axilla. The accuracy of the BCN was determined in this clinically relevant range.

Results

The predictive accuracy of the BCN had an area under the ROC curve of 0.687. Almost half of interviewed surgeons treat over 20 breast cancer per year. Fourteen out of 82 surgeons questioned would never leave the patient without a completion axillary dissection after a positive SLN, regardless of the BCN result. Seventy one percent of them would not complete axillary dissection if the prediction of a positive NSLN was ≤10%. Only 37 of the 209 patients were in this 10% or less category, with a mean observed rate of positive NSLN of 13% (95% confidence interval [CI], 2–24%).

Conclusion

The global performance of the BCN was fair. A majority of surgeons in Quebec would omit an axillary lymph node dissection (ALND) if the predicted probability of positive NSLN is 10% or less. Although useful, the BCN data should be used with caution at the low end of the scale. Because of some limitations in the performance in this category, other clinical factors and judgment must accompany its use.
Literatur
1.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology, American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703–20PubMedCrossRef Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology, American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703–20PubMedCrossRef
2.
Zurück zum Zitat Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996; 131:301–8PubMed Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996; 131:301–8PubMed
3.
Zurück zum Zitat Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657–63PubMedCrossRef Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657–63PubMedCrossRef
4.
Zurück zum Zitat Fisher B, Redmond C, Fisher E. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Surg 1985; 312:674–81 Fisher B, Redmond C, Fisher E. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Surg 1985; 312:674–81
5.
Zurück zum Zitat Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol 1997; 66:7–10PubMedCrossRef Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol 1997; 66:7–10PubMedCrossRef
6.
Zurück zum Zitat Van Zee KJ, Manasseh D-ME, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2003; 10:1140–51PubMedCrossRef Van Zee KJ, Manasseh D-ME, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2003; 10:1140–51PubMedCrossRef
7.
Zurück zum Zitat Kocsis L, Svébis M, Boross G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 2004; 70:1019–24PubMed Kocsis L, Svébis M, Boross G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 2004; 70:1019–24PubMed
8.
Zurück zum Zitat Soni NK, Carmalt HL, Gillett DJ, et al. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol 2005; 31:958–64PubMedCrossRef Soni NK, Carmalt HL, Gillett DJ, et al. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol 2005; 31:958–64PubMedCrossRef
9.
Zurück zum Zitat Smidt ML, Kuster DM, van der Wilt GJ, et al. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastasis in breast cancer patients in the Netherlands? Ann Surg Oncol 2005; 12:1066–72PubMedCrossRef Smidt ML, Kuster DM, van der Wilt GJ, et al. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastasis in breast cancer patients in the Netherlands? Ann Surg Oncol 2005; 12:1066–72PubMedCrossRef
10.
Zurück zum Zitat Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003; 98:2307–15PubMedCrossRef Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003; 98:2307–15PubMedCrossRef
11.
Zurück zum Zitat Specht MC, Kattan MW, Gonen M, et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12:654–9PubMedCrossRef Specht MC, Kattan MW, Gonen M, et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12:654–9PubMedCrossRef
12.
Zurück zum Zitat Cripe MH, Beran LC, Liang WC, et al. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg 2006; 192:484–7PubMedCrossRef Cripe MH, Beran LC, Liang WC, et al. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg 2006; 192:484–7PubMedCrossRef
13.
Zurück zum Zitat Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastasis after a positive sentinel node biopsy. Ann Surg Oncol 2006; 13:310–20PubMedCrossRef Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastasis after a positive sentinel node biopsy. Ann Surg Oncol 2006; 13:310–20PubMedCrossRef
14.
Zurück zum Zitat Zgajnar J, Perhavec A, Hocevar M, et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol 2007; 96:547–53PubMedCrossRef Zgajnar J, Perhavec A, Hocevar M, et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol 2007; 96:547–53PubMedCrossRef
15.
Zurück zum Zitat Ponzone R, Maggiorotto F, Mariani L, et al. Comparison of two models for the prediction of nonsentinel node metastasis in breast cancer. Am J Surg 2007; 193:686–92PubMedCrossRef Ponzone R, Maggiorotto F, Mariani L, et al. Comparison of two models for the prediction of nonsentinel node metastasis in breast cancer. Am J Surg 2007; 193:686–92PubMedCrossRef
16.
Zurück zum Zitat Alran S, De Rycke Y, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 2007; 14:2195–201PubMedCrossRef Alran S, De Rycke Y, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 2007; 14:2195–201PubMedCrossRef
17.
Zurück zum Zitat Pal A, Provenzano E, Duffy SW, et al. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 2007; 95:302–9CrossRef Pal A, Provenzano E, Duffy SW, et al. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 2007; 95:302–9CrossRef
18.
Zurück zum Zitat Klar M, Jochmann A, Foeldi M, et al. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat 2008; Jan 3 (Epub ahead of print) Klar M, Jochmann A, Foeldi M, et al. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat 2008; Jan 3 (Epub ahead of print)
19.
Zurück zum Zitat Fischer JE, Bachman LM, Jaeschke R. A reader’s guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29:1043–51PubMedCrossRef Fischer JE, Bachman LM, Jaeschke R. A reader’s guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29:1043–51PubMedCrossRef
20.
Zurück zum Zitat Benson RB, della Rovere GQ. Axilla Management Consensus Group (2007). Management of the axilla in women with breast cancer. Lancet Oncol 2007; 8:331–48PubMedCrossRef Benson RB, della Rovere GQ. Axilla Management Consensus Group (2007). Management of the axilla in women with breast cancer. Lancet Oncol 2007; 8:331–48PubMedCrossRef
21.
Zurück zum Zitat Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109–16PubMedCrossRef Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109–16PubMedCrossRef
22.
Zurück zum Zitat National Surgical Adjuvant Breast and Bowel Project (NSABP) B–32: a randomized Phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node negative breast cancer patients. http://www.nsabp.pitt.edu/ (accessed Feb 2008) National Surgical Adjuvant Breast and Bowel Project (NSABP) B–32: a randomized Phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node negative breast cancer patients. http://​www.​nsabp.​pitt.​edu/ (accessed Feb 2008)
23.
Zurück zum Zitat Glimberty V. International Breast Cancer Study Group trial of sentinel node biopsy. J Clin Oncol 2006; 24:210–1CrossRef Glimberty V. International Breast Cancer Study Group trial of sentinel node biopsy. J Clin Oncol 2006; 24:210–1CrossRef
Metadaten
Titel
Analysis of Clinical Applicability of the Breast Cancer Nomogram for Positive Sentinel Lymph Node: The Canadian Experience
verfasst von
Éric Poirier, MD, FRCSC
Lucas Sideris, MD, FRCSC
Pierre Dubé, MD, MSc, FRCSC, FACS
Pierre Drolet, MD, FRCPC
Sarkis H. Meterissian, MD, FRCSC, FACS
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0033-9

Weitere Artikel der Ausgabe 9/2008

Annals of Surgical Oncology 9/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.